ASN
KZR

Advisory Services Network’s Kezar Life Sciences KZR Stock Holding History

Advisory Services Network’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30
Closed -$1K – 3509
2020
Q3 		$1K Buy
+30
New +$1.44K ﹤0.01% 3341

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Advisory Services Network's KZR Position: Q4 2020 in Review

Advisory Services Network sold out of Kezar Life Sciences (KZR) in Q4 2020, closing a stake of 30 shares — an estimated $1K sold.

Advisory Services Network first reported a position in KZR in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 77 funds tracked by Wall St. Rank hold KZR as of Q4 2020.

  • Advisory Services Network reported no remaining Kezar Life Sciences position as of Q4 2020 after selling out during the quarter.
  • Advisory Services Network sold 30 Kezar Life Sciences shares in Q4 2020, an estimated $1K.
  • Advisory Services Network first reported a position in Kezar Life Sciences in Q3 2020 and held it in 1 quarter.
  • Advisory Services Network's Kezar Life Sciences position peaked at $1K in Q3 2020.
  • 77 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2020.

Based on Advisory Services Network's 13F filing for Q4 2020, filed 9 Feb 2021.